Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule
or Standard; Transfer of Listing.
On March 16, 2023, Evelo Biosciences, Inc. (the "Company") received a letter
from the Listing Qualifications Department of The Nasdaq Stock Market LLC
("Nasdaq") notifying the Company that, for the last 30 consecutive business
days, the bid price for the Company's common stock, par value $0.001 per share
(the "Common Stock"), had closed below the $1.00 per share minimum bid price
requirement for continued inclusion on the Nasdaq Global Select Market pursuant
to Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Requirement").
The letter has no immediate effect on the listing of the Common Stock on the
Nasdaq Global Select Market, and the Common Stock will continue to trade on The
Nasdaq Global Select Market under the symbol "EVLO," subject to the Company's
compliance with the other continued listing requirements of The Nasdaq Global
Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company
has been provided an initial compliance period of 180 calendar days from receipt
of the letter, or until September 12, 2023, to regain compliance with the Bid
Price Requirement. To regain compliance, the closing bid price for the Common
Stock must be at least $1.00 per share for a minimum of 10 consecutive business
days prior to September 12, 2023. There can be no assurance that the Company
will be able to regain compliance or that Nasdaq will extend the compliance
period.
If the Company does not regain compliance with the Bid Price Requirement by
September 12, 2023, the Company may be eligible for an additional 180 calendar
day compliance period. To qualify, the Company must submit an application to
transfer the listing of the Common Stock to The Nasdaq Capital Market, which
requires the Company to meet the continued listing requirement for the market
value of publicly held shares and all other initial listing standards for The
Nasdaq Capital Market, other than the Bid Price Requirement. The Company would
also need to pay an application fee to Nasdaq and to provide written notice of
its intention to cure the deficiency during the additional compliance period. As
part of its review process, Nasdaq will make a determination of whether it
believes the Company will be able to cure this deficiency.
If the Company does not regain compliance within the compliance period(s),
Nasdaq will provide written notification to the Company that the Common Stock
will be subject to delisting. At that time, the Company may appeal the delisting
determination to a Nasdaq Listing Qualifications Panel. There can be no
assurance that, if the Company decides to appeal the delisting determination,
such appeal would be successful.
The Company intends to monitor the closing bid price of the Common Stock and
may, if appropriate, consider taking actions to regain compliance with the Bid
Price Requirement, including, subject to approval of the Company's Board of
Directors and stockholders, implementing a reverse stock split. There can be no
assurance that the Company will be able to regain compliance with the Bid Price
Requirement or will otherwise be in compliance with other applicable Nasdaq
listing rules.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses